GlaxoSmithKline toes the line in Breo launch

Does the Justice Department's off-label marketing enforcement actually deter bad behavior? That's been up for debate as one drugmaker after another agreed to pay hundreds of millions of dollars to settle federal investigations--some of them repeat offenders. Some drugmakers appear to be changing their behavior, though, Bloomberg reports--not out of the goodness of their hearts, but out of self-interest. Story